Acetylcholine

Acetylcholine
Pharmillustrator · CC0 · source
Name	Acetylcholine
IUPAC name	2-(acetyloxy)-N,N,N-trimethylethanaminium
CAS number	62-31-7
Formula	C7H16NO2+
Molar mass	146.21 g·mol−1

Acetylcholine

Introduction

Acetylcholine is a quaternary ammonium neurotransmitter discovered in studies linked to Otto Loewi, Henry Dale, Nobel Prize in Physiology or Medicine, University of Graz, and University of Oxford. It was central to early 20th-century investigations at institutions including Kaiser Wilhelm Society, Rockefeller Institute for Medical Research, Johns Hopkins University, and University of Cambridge. Key figures such as Paul Ehrlich, Walter Cannon, Ernst Neumann, and Sir Henry Dale contributed to its characterization, which influenced research at Harvard Medical School, Columbia University, University of Berlin, Max Planck Society, and Pasteur Institute.

Biosynthesis and Metabolism

Acetylcholine synthesis occurs predominantly in cholinergic neurons within regions studied by Santiago Ramón y Cajal and techniques developed at Mayo Clinic, Karolinska Institutet, and Massachusetts Institute of Technology. The synthetic enzyme choline acetyltransferase (ChAT) was identified through biochemical work at Princeton University and University College London, while uptake mechanisms involve transporters characterized in labs at Stanford University and University of California, San Francisco. Degradation is mediated by acetylcholinesterase (AChE), a protein whose inhibitors were explored by researchers at ETH Zurich, Wistar Institute, Institute Pasteur, and Brookhaven National Laboratory. Studies at National Institutes of Health and Food and Drug Administration laboratories clarified metabolic pathways relevant to exposures investigated by World Health Organization and Centers for Disease Control and Prevention.

Receptor Types and Signaling

Cholinergic signaling engages distinct receptor families elucidated through structural biology at European Molecular Biology Laboratory, Rutherford Appleton Laboratory, and Cold Spring Harbor Laboratory. Ionotropic nicotinic receptors were analyzed in collaborations involving Salk Institute, Wellcome Trust Sanger Institute, and Max Delbrück Center, while metabotropic muscarinic receptors were characterized in projects at Imperial College London, University of Edinburgh, and Yale University. Crystallographic and cryo-EM advances at Lawrence Berkeley National Laboratory, Argonne National Laboratory, and Brookhaven National Laboratory informed models that intersect with investigations at Howard Hughes Medical Institute and Howard University.

Physiological Roles

Acetylcholine mediates functions across systems explored in clinical centers such as Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. In the peripheral nervous system, cholinergic transmission governs processes studied in surgical units at Mount Sinai Hospital and Massachusetts General Hospital, while central cholinergic pathways affecting cognition were mapped in neuroimaging programs at National Institutes of Health, McGill University, and University of Toronto. Developmental and aging-related roles were subjects of longitudinal cohorts coordinated by Framingham Heart Study, Baltimore Longitudinal Study of Aging, and research networks like European Brain Council.

Pharmacology and Therapeutic Uses

Pharmacological modulation of cholinergic signaling has produced therapeutics developed by pharmaceutical companies such as Pfizer, Merck & Co., GlaxoSmithKline, and Novartis. Acetylcholinesterase inhibitors and receptor agonists/antagonists emerged from programs at AstraZeneca, Eli Lilly and Company, Roche, and Bayer AG. Clinical trials conducted under protocols from World Health Organization, European Medicines Agency, and U.S. Food and Drug Administration evaluated agents in settings including Massachusetts General Hospital, Royal Infirmary of Edinburgh, and Guy's and St Thomas' NHS Foundation Trust. Historical military and agricultural applications were examined in studies linked to Los Alamos National Laboratory, Edgewood Arsenal, and regulatory reviews by Environmental Protection Agency.

Clinical Significance and Disorders

Alterations in cholinergic systems are implicated in disorders characterized in cohorts at Alzheimer's Disease Research Center, Parkinson's Disease Foundation, and National Multiple Sclerosis Society. Myasthenia gravis, diagnosed and managed in clinics such as Mayo Clinic and Cleveland Clinic, involves antibodies identified through immunology studies at Rockefeller University and La Jolla Institute for Immunology. Organophosphate poisoning cases investigated by Centers for Disease Control and Prevention and military medicine units at Walter Reed National Military Medical Center highlight acetylcholinesterase inhibition, with antidotes developed via programs at Naval Research Laboratory and Defense Advanced Research Projects Agency. Neuropsychiatric and cognitive disorders associated with cholinergic deficits were the focus of translational research at King's College London, University College London, and Scripps Research.

Category:Neurotransmitters